VJOncology is committed to improving our service to you

GU Cancers 2019 | Prognostic value of cytogenic findings in RCC

VJOncology is committed to improving our service to you

Cedric Lebacle

Cedric Lebacle, of the University of Paris-Sud, Orsay, France, discusses the integration of genomic alterations with clinical and pathologic outcomes in renal cell carcinoma (RCC). This interview was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Transcript (edited for clarity):

We implemented cytolytic findings to clinical parameters, such as loss of 10q, again a 5q which is a better prognosis factor, also loss of sexual chromosome for T3 pathologic patients.

The main finding of this classification, the accuracy of the high-risk group is 83% to predict high-risk recurrence. It’s better than the other classification whose previews I assess with an IUC for 0.72 versus 0.65, so it’s significantly better.


Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter